High-Dose Olanzapine for Treatment-Refractory Schizophrenia
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
To date there is no common or adequate therapeutic strategy for treatment of refractory schizophrenic patients. Increasing antipsychotics' doses in treatment-resistant schizophrenic patients is the most common intervention used by clinicians. Olanzapine is an atypical antipsychotic, which in a number of double-blind, placebo-controlled studies has been found to be more effective than haloperidol for the treatment of positive and negative symptoms of schizophrenia. During the last few years there have been several reports of successful results in prescribing olanzapine at dosages of more than 25 mg/day for treatment-resistant schizophrenic and schizoaffective patients. This report presents the results from the treatment of three resistant schizophrenic patients treated successfully with high dosages of olanzapine (35, 40, and 60 mg/day). None of the patients had any side effects, including abnormal laboratory levels and weight gain. The results and literature data suggest that in clinical practice some schizophrenic patients resistant to conventional neuroleptic treatment and not responding to olanzapine at recommended dosages as high as 20 mg/day may respond to higher dosages such as 40 or 60 mg/day, and these dosages are well tolerated. Further prospective clinical studies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is also some evidence that high doses of certain antidepressants (e.g. venlafaxine) 53, 89 or antipsychotics (e.g. olanzapine) 52 can be effective strategies in the management of treatment resistant depression and schizophrenia respectively.”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [52]
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Nordström, A.-L., Farde, L., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370 · cited 1×
“The low rate of extrapyramidal symptoms at a high dose of olanzapine may be the result of a combination of relatively low striatal D2 occupancy and higher 5-HT2 receptor antagonism, and olanzapine built-in anticholinergic activity at higher doses (14,28).”
BackgroundBeasley, C. M., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., & Beuzen, J.-N. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00392-6 · Cited by 277
Evaluation of Treatment-Resistant Schizophrenia
Conley, R. R., & Buchanan, R. W. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.663 · Cited by 238
Pharmacologic activation of limbic structures and neuroimaging studies of emotions.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997) · PubMed · Cited by 209
Research works printed but not linked: 5
- Daniel, 1998, J Clin Psychiatry, 59, 13
- Marder, 1996, J Clin Psychiatry, 57, 26
- Beasley, 1997, J Clin Psychiatry, 58, 13
- Kane, 1999, J Clin Psychiatry, 60, 13
- Peuskens, 1999, J Clin Psychiatry, 60, 4
Cited by
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Iasevoli, F., Giordano, S., Balletta, R., Latte, G., Formato, M. V., Prinzivalli, E., De Berardis, D., Tomasetti, C., & de Bartolomeis, A. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.08.010 · Cited by 176
Antipsychotic Dosing: How Much but also How Often?
Remington, G., & Kapur, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq083 · Cited by 65
Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence
Pandurangi, A., & Dalkiliç, A. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000341890.05383.45 · Cited by 65
Kogut, S. J., Yam, F. K., & Dufresne, R. L. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.1.17 · Cited by 50
Metadata
- Authors
- Lerner, V.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Lerner, Vladimir
- ORCID
- Lerner, Vladimir
- Venue
- Clinical Neuropharmacology
- Published
- 2003-03
- Volume
- 26
- Issue
- 2
- Pages
- 58-61
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W1973272294
- Cited by
- 29
- References
- 29
- Citations by year
- 2022: 1 · 2021: 1 · 2020: 1 · 2018: 4 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- olanzapine, high-dose antipsychotics, treatment-resistant schizophrenia, atypical antipsychotics, dose escalation, schizoaffective disorder, adverse effects, weight gain
- MeSH terms
- Olanzapine, Adult, Benzodiazepines, Female, Humans, Male, Pirenzepine, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Dose Olanzapine for Treatment-Refractory Schizophrenia. https://app.cochat.ai/papers/10.1097/00002826-200303000-00003
- The paper
- Lerner, V. (2003). High-Dose Olanzapine for Treatment-Refractory Schizophrenia. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-200303000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.